自2017年以来，免疫检查点抑制剂（ICIs）已可用于治疗晚期肝细胞癌（HCC）或不可切除的HCC，但其纳入国家医疗保险计划的程度仍然有限​​。成本效益证据有助于为治疗决策提供信息。本系统综述旨在对 ICI 作为晚期 HCC 治疗方法的经济评估进行重要总结，并确定关键驱动因素（PROSPERO 2023：CRD42023417391）。使用的数据库包括 Scopus、Web of Science、PubMed、Embase 和 Cochrane Central。其中包括 ICI 治疗晚期 HCC 的经济评估。研究由两个人筛选。在已识别的 898 条记录中，包含 17 篇文章。目前的证据表明，与酪氨酸激酶抑制剂相比，ICIs，包括atezolizumab加贝伐单抗、信迪利单抗加贝伐单抗/贝伐单抗生物仿制药、nivolumab、camrelizumab加rivoceranib、pembrolizumab加乐伐替尼、替雷利珠单抗、durvalumab和卡博替尼加atezolizumab，可能不具有成本效益。或其他 ICI。最有影响力的参数是抗癌药物的价格、无进展生存期和总生存期的风险比以及健康状态的效用。我们的审查表明，ICIs 对于晚期 HCC 来说并不是一种具有成本效益的干预措施。尽管 ICI 可以显着提高晚期 HCC 患者的生存率，但决策者在采用新疗法之前应考虑经济评估结果和负担能力。© 2024。作者。

Since 2017, immune checkpoint inhibitors (ICIs) have been available for the treatment of advanced hepatocellular carcinoma (HCC) or unresectable HCC, but their adoption into national medical insurance programs is still limited. Cost-effectiveness evidence can help to inform treatment decisions. This systematic review aimed to provide a critical summary of economic evaluations of ICIs as a treatment for advanced HCC and identify key drivers (PROSPERO 2023: CRD42023417391). The databases used included Scopus, Web of Science, PubMed, Embase, and Cochrane Central. Economic evaluations of ICIs for the treatment of advanced HCC were included. Studies were screened by two people. Of the 898 records identified, 17 articles were included. The current evidence showed that ICIs, including atezolizumab plus bevacizumab, sintilimab plus bevacizumab/bevacizumab biosimilar, nivolumab, camrelizumab plus rivoceranib, pembrolizumab plus lenvatinib, tislelizumab, durvalumab, and cabozantinib plus atezolizumab, are probably not cost-effective in comparison with tyrosine kinase inhibitors or other ICIs. The most influential parameters were price of anticancer drugs, hazard ratios for progression-free survival and overall survival, and utility for health statest. Our review demonstrated that ICIs were not a cost-effective intervention in advanced HCC. Although ICIs can significantly enhance the survival of patients with advanced HCC, decision-makers should consider the findings of economic evaluations and affordability before adoption of new therapies.© 2024. The Author(s).